Vestronidase
- TRADE NAME: Mepsevii (Ultragenyx)
- INDICATIONS: Mucopolysaccharidosis VII (Sly syndrome)
- CLASS: Enzyme replacement
- HALF-LIFE: 51–213 minutes
FDA APPROVAL DATE: 11/15/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
No available data to determine drug-associated risk
ANAPHYLAXIS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
GASTROINTESTINAL/HEPATIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric